[go: up one dir, main page]

WO2009027077A3 - 5-arylalkyliden-2-arylalkyl-thiazol-4-onderivate als inhibitoren der 5-lipoxygenase und deren verwendungen - Google Patents

5-arylalkyliden-2-arylalkyl-thiazol-4-onderivate als inhibitoren der 5-lipoxygenase und deren verwendungen Download PDF

Info

Publication number
WO2009027077A3
WO2009027077A3 PCT/EP2008/007014 EP2008007014W WO2009027077A3 WO 2009027077 A3 WO2009027077 A3 WO 2009027077A3 EP 2008007014 W EP2008007014 W EP 2008007014W WO 2009027077 A3 WO2009027077 A3 WO 2009027077A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
lipoxygenase
inhibitors
arylalkylidene
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/007014
Other languages
English (en)
French (fr)
Other versions
WO2009027077A2 (de
WO2009027077A8 (de
Inventor
Gisbert Schneider
Dieter Steinhilber
Lutz Franke
Bettina Hofmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Publication of WO2009027077A2 publication Critical patent/WO2009027077A2/de
Publication of WO2009027077A8 publication Critical patent/WO2009027077A8/de
Publication of WO2009027077A3 publication Critical patent/WO2009027077A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Die vorliegende Erfindung bezieht sich auf trizyklische ThiazoIon-Verbindungen und auf Imidazopyridin-Verbindungen als neuartige und effektive Inhibitoren der 5-Lipoxygenase und deren Einfluß auf den Arachidonsäure-Stoffwechsel. Die Verbindungen sind geeignet zur Behandlung von Erkrankungen, insbesondere von Leukotrien-vermittelten Erkrankungen, wie Entzündungskrankheiten, allergischen Erkrankungen, kardiovaskulären Erkrankungen, Osteoporose, Haarausfall und weiteren.
PCT/EP2008/007014 2007-08-27 2008-08-27 5-arylalkyliden-2-arylalkyl-thiazol-4-onderivate als inhibitoren der 5-lipoxygenase und deren verwendungen Ceased WO2009027077A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007040336A DE102007040336A1 (de) 2007-08-27 2007-08-27 Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
DE102007040336.6 2007-08-27

Publications (3)

Publication Number Publication Date
WO2009027077A2 WO2009027077A2 (de) 2009-03-05
WO2009027077A8 WO2009027077A8 (de) 2009-04-30
WO2009027077A3 true WO2009027077A3 (de) 2009-09-24

Family

ID=40298809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/007014 Ceased WO2009027077A2 (de) 2007-08-27 2008-08-27 5-arylalkyliden-2-arylalkyl-thiazol-4-onderivate als inhibitoren der 5-lipoxygenase und deren verwendungen

Country Status (2)

Country Link
DE (1) DE102007040336A1 (de)
WO (1) WO2009027077A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005721A1 (en) * 2009-09-23 2013-01-03 Panmira Pharmaceuticals, Llc Indolizine inhibitors of 5-lipoxygenase
EP2480548A4 (de) * 2009-09-23 2013-02-20 Panmira Pharmaceuticals Llc Indolizinhemmer aus 5-lipoxygenase
EP2601191A4 (de) * 2010-08-03 2013-07-31 Univ California Verbindungen und zusammensetzungen zur milderung von gewebeschäden und letalität
US9029389B2 (en) * 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
US9540366B2 (en) 2012-07-31 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic compound
CN108689960B (zh) * 2018-06-07 2022-03-04 济南大学 5-苯亚甲基-2-苯基噻唑酮类化合物及其制备和应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304493A1 (de) * 1987-03-11 1989-03-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyren-derivate
WO2001027109A2 (de) * 1999-10-08 2001-04-19 Grünenthal GmbH Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate
WO2002030428A1 (de) * 2000-10-13 2002-04-18 Grünenthal GmbH Verwendung von substituierten imidazo[1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung
WO2002090911A1 (en) * 2001-05-07 2002-11-14 Flir Systems Ab Handheld infrared camera
WO2004028464A2 (en) * 2002-09-27 2004-04-08 University Of North Carolina At Chapel Hill Methods and compositions for modification of splicing of pre-mrna
WO2005007141A2 (en) * 2003-07-11 2005-01-27 Proteologics, Inc. Ubiquitin ligase inhibitors and methods related thereto
US20050042213A1 (en) * 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
WO2005105798A1 (de) * 2004-04-30 2005-11-10 Grünenthal GmbH Substituierte imidazo[1,2-a] pyridin-verbindungen und arzneimittel enthaltend substituierte imidazo [1,2-a] pyridin-verbindungen
WO2006122777A2 (de) * 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln
WO2007067711A2 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
WO2007073503A2 (en) * 2005-12-21 2007-06-28 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005063833A (ja) 2003-08-13 2005-03-10 Mitsubishi Paper Mills Ltd 光電変換材料、半導体電極並びにそれを用いた光電変換素子
WO2005082363A1 (en) * 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
CN101218238B (zh) 2005-03-21 2011-10-26 S*Bio私人有限公司 咪唑并[1,2-a]吡啶衍生物：制备及药学应用
DE102005019181A1 (de) 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CN101228171A (zh) 2005-07-26 2008-07-23 默克勒有限公司 作为5-脂氧化酶和环加氧酶抑制剂的吡咯里嗪和中氮茚化合物的大环内酯偶联物
US20090023742A1 (en) * 2006-03-02 2009-01-22 Dashyant Dhanak Thiazolones for use as pi3 kinase inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304493A1 (de) * 1987-03-11 1989-03-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyren-derivate
WO2001027109A2 (de) * 1999-10-08 2001-04-19 Grünenthal GmbH Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate
WO2002030428A1 (de) * 2000-10-13 2002-04-18 Grünenthal GmbH Verwendung von substituierten imidazo[1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung
WO2002090911A1 (en) * 2001-05-07 2002-11-14 Flir Systems Ab Handheld infrared camera
WO2004028464A2 (en) * 2002-09-27 2004-04-08 University Of North Carolina At Chapel Hill Methods and compositions for modification of splicing of pre-mrna
WO2005007141A2 (en) * 2003-07-11 2005-01-27 Proteologics, Inc. Ubiquitin ligase inhibitors and methods related thereto
US20050042213A1 (en) * 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
WO2005105798A1 (de) * 2004-04-30 2005-11-10 Grünenthal GmbH Substituierte imidazo[1,2-a] pyridin-verbindungen und arzneimittel enthaltend substituierte imidazo [1,2-a] pyridin-verbindungen
WO2006122777A2 (de) * 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln
WO2007067711A2 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
WO2007073503A2 (en) * 2005-12-21 2007-06-28 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BROQUET, COLETTE ET AL: "Synthesis and chemical behavior of 5H-2-aryl-4-thiazolones", COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES, SERIE C: SCIENCES CHIMIQUES , 262(12), 1017-20 CODEN: CHDCAQ; ISSN: 0567-6541, 1966, XP009112056 *
CULVENOR ET AL., JOURNAL OF THE CHEMICAL SOCIETY, 1949, pages 2573 - 2577, XP002152934 *
DAS, ET AL., JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 31, 1954, pages 617 - 619, XP009112004 *
LESYK, ROMAN ET AL: "Synthesis and antiinflammatory activity of some 2-arylamino-2-thiazolin-4-ones", ACTA POLONIAE PHARMACEUTICA , 60(6), 457-466 CODEN: APPHAX; ISSN: 0001-6837, 2003, XP009112165 *
ROUT, M., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 77, 1955, pages 2427 - 2428, XP009112000 *
SCHMITT, M. ET AL., AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 50, no. 7, 1997, pages 719 - 726, XP001010372 *
STEPANOV, F. N. ET AL: "4-Hydroxythiazoles. II. Reactions of the methylene group of 2-phenyl-2-thiazolin-4-one", ZHURNAL OBSHCHEI KHIMII , 25, 1923-6 CODEN: ZOKHA4; ISSN: 0044-460X, 1955, XP009112002 *
ZAYED ET AL., PHARMAZIE, vol. 40, no. 3, 1985, pages 194 - 196, XP001538685 *

Also Published As

Publication number Publication date
WO2009027077A2 (de) 2009-03-05
DE102007040336A1 (de) 2009-03-05
WO2009027077A8 (de) 2009-04-30

Similar Documents

Publication Publication Date Title
IL272817A (en) New preparations and methods for the treatment of vaccine-related diseases
WO2009134389A9 (en) An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
WO2011053940A3 (en) Templated nanoconjugates
EP2244709A4 (de) Topische formulierungen zur behandlung von psoriasis
WO2007115821A3 (en) Organic compounds
WO2011041399A3 (en) Pi3k (delta) selective inhibitors
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
WO2014007951A3 (en) Substituted tricyclic compounds as fgfr inhibitors
BR112012025685A2 (pt) ''método de aumento da capacidade de retenção de água (cra), fração de farelo de cereal, uso, produto alimentício e kit''
WO2009027077A3 (de) 5-arylalkyliden-2-arylalkyl-thiazol-4-onderivate als inhibitoren der 5-lipoxygenase und deren verwendungen
CL2013000455A1 (es) Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer.
ZA201100653B (en) Topical composition for the treatment of ctinic keratosis
WO2010079914A3 (en) A composition comprising the compound isolated from the extract of rubiae radix for preventing and treating inflammatory diseases
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2010051138A3 (en) Skin treatments containing carboxylic acid-substituted idebenone derivatives and methods of preparation and use thereof
WO2011048616A3 (en) Healthy sugar and process for preparation of the same
WO2010056741A3 (en) Phenylacetic acid inhibitors of cyclooxygenase
WO2008037497A3 (en) Galectin-2 for the treatment of inflammatory diseases of the skin
WO2012087434A3 (en) Use of phosphoric acid for treating cardiovascular disorders
WO2011069149A3 (en) Cathepsin s inhibitors
WO2012051323A3 (en) Cryptophane derivatives and methods of use thereof
WO2012018980A3 (en) Compositions and methods for treating inflammatory diseases
WO2010127264A3 (en) HNF4α ANTAGONISTS AND METHODS OF USE
WO2011139254A3 (en) Pharmaceutical formulations compising cefuroxime axetil
WO2008093221A3 (en) Pharmaceutical compositions containing pde4 inhibitor for the treatment of inflammatory and allergic disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08785715

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08785715

Country of ref document: EP

Kind code of ref document: A2